Antiphospholipid Syndrome Clinical Trial
Official title:
A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome (RITAPS)
RITuximab AntiphosPholipid Syndrome (RITAPS) Study is designed to evaluate whether a medication called rituximab would reduce the signs and symptoms of antiphospholipid antibody (aPL) -related certain clinical problems.
Persistently antiphospholipid antibody (aPL)-positive patients, age 18 - 75 years of age,
with anticoagulation-resistant manifestations of APS and fulfilling protocol defined study
inclusion criteria will receive two doses of Rituximab, and will be followed for 6 and 12
months for clinical and safety outcomes, respectively.
Patients are eligible to take part in this study if their blood test is persistently positive
for aPL and they have one or more of the aPL-related clinical problem(s) listed below: low
platelet (blood cells involved in the prevention of bleeding) count; anemia (deficiency of
red blood cells); heart valve disease; skin ulcers; kidney smal vessel blood clots; and/or
memory problems.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01475149 -
Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
|
N/A | |
| Recruiting |
NCT00616317 -
Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study
|
||
| Recruiting |
NCT00198068 -
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
|
||
| Completed |
NCT00180817 -
Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies.
|
||
| Completed |
NCT03682419 -
Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)
|
N/A | |
| Not yet recruiting |
NCT03303508 -
Measurement of Anti-dsDNA by Both CLIFT & ELISA
|
N/A | |
| Recruiting |
NCT04262492 -
International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
|
||
| Withdrawn |
NCT00180778 -
Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT05583305 -
Prevalence and Etiologies of Intracranial Stenosis in Patients With Antiphospholipid Syndrome
|
||
| Recruiting |
NCT05644210 -
Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE
|
||
| Recruiting |
NCT02303171 -
Use of Warfarin After the First Trimester in Pregnant Women With APS
|
Phase 4 | |
| Completed |
NCT00674297 -
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
|
Phase 2 | |
| Recruiting |
NCT05859997 -
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
|
N/A | |
| Recruiting |
NCT06373003 -
Negative Antiphospholipid Syndrome: a Multicentric Study
|
||
| Recruiting |
NCT06373926 -
Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome
|
N/A | |
| Recruiting |
NCT01818505 -
The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome
|
N/A | |
| Completed |
NCT00878137 -
Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin
|
N/A | |
| Completed |
NCT01104337 -
Drug Interaction Between Paracetamol and Warfarin
|
Phase 4 | |
| Completed |
NCT05313048 -
Prospective Observational Study to Evaluate a Possible Change in APS Antibody Profiles After COVID-19 Infection or Vaccination
|
||
| Recruiting |
NCT03890601 -
New Biological Tests in Patients With Antiphospholipid Antibodies
|